CMS tightens the test for real generic competition

A generic drug can win Food and Drug Administration approval and still fail to count as real competition for Medicare. The Centers for Medicare & Medicaid Services, or CMS, is proposing to look at the totality of the circumstances before deciding whether an approved generic or biosimilar, a copy of a biologic drug, is engaged in bona fide marketing in Medicare’s Drug Price Negotiation Program.

That matters because the answer can decide whether a selected drug stays in the negotiation program or is later deselected. Under the proposal, token or de minimis availability would not be enough to change a drug’s status.

Paper approval is not the finish line

CMS says it would not rely on one factor alone. Instead, the agency would make a holistic inquiry, taking in the full set of circumstances rather than treating approval on paper as proof that a rival is actually competing.

The timing of that review also matters. CMS would judge whether competition exists when it evaluates the product, not simply when the generic or biosimilar first gets approved. That leaves room for a drug to be cleared by FDA and still fall short if it is barely available or not meaningfully marketed.

Why patients and manufacturers care

For Medicare beneficiaries, generic drug makers, biosimilar manufacturers and drug makers with products in the program, the practical question is plain: when is a lower-cost rival real enough to change a drug’s fate? CMS’s answer will turn on the whole market picture it sees at the time of review.

That makes the policy less about a single document and more about whether competition is real in the marketplace. If the agency decides the answer is no, a selected drug can remain in negotiation longer than manufacturers might expect from approval alone.